Oral GLP-1 drugs may quiet the brain’s food craving circuit
Newer oral drugs related to semaglutide medications such as Ozempic reduced pleasure-driven eating in mice by quieting a deep brain reward circuit.
The finding could open new avenues for understanding food cravings and potentially treating substance use disorder. This research highlights the potential therapeutic applications of oral GLP-1 drugs in modulating brain reward circuits. Further studies are needed to fully elucidate the mechanisms underlying these effects and to explore their potential in humans.